Inhibition of miR-93-5p promotes osteogenic differentiation in a rabbit model of trauma-induced osteonecrosis of the femoral head

Running title: MiR-93-5p and osteogenic differentiation

Ying Zhang¹ ² #, Zhikun Zhuang² #, Qiushi Wei³ ⁴, Peifeng Li¹, Jitian Li¹, Yanan Fan¹, Leilei Zhang¹, Zhinan Hong³ ⁴, Wei He³ ⁴, Haibin Wang², Youwen Liu¹*, Wuyin Li¹*

¹Medical Center of Hip, Luoyang Orthopedic-Traumatological Hospital (Orthopedics Hospital of Henan Province), Luoyang 471002, Henan Province, China
²Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
³Institute of Orthopaedics of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
⁴The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510240, Guangdong Province, China

#Contributed equally to this work.

*Corresponding authors: Wuyin Li and Youwen Liu

Medical Center of Hip, Luoyang Orthopedic-Traumatological Hospital (Orthopedics Hospital of Henan Province), Luoyang 471002, Henan Province, China

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/2211-5463.13218

FEBS Open Bio (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Abbreviations

ONFH, osteonecrosis of the femoral head; TIONFH, trauma-induced osteonecrosis of the femoral head; BMSCs, bone marrow mesenchymal stem cells; miRNAs, microRNAs; BMP-2, bone morphogenetic protein 2; MRI, magnetic resonance imaging; qPCR, quantitative polymerase chain reaction; IHC, immunohistochemical; ALP, alkaline phosphatase; TBS, tris-buffered saline; OPN, secreted phosphoprotein 1; RUNX-2, RUNX family transcription factor 2; NC, negative control; OPG, TNF receptor superfamily member 11b; RANKL, receptor activator of nuclear factor-kappaB Ligand; SD, standard deviation.

Abstract

Trauma-induced osteonecrosis of the femoral head (TIONFH) is characterized by femoral head collapse accompanied by degenerative changes of the hip. We previously reported that miR-93-5p expression is abnormally high in TIONFH patients, but the role of miR-93-5p in the TIONFH process remains unclear. Herein, we investigated the role of miR-93-5p in TIONFH in a rabbit model. Bone marrow mesenchymal stem cells (BMSCs) were used for both in vivo and in vitro experiments. A rabbit model of TIONFH was injected with BMSCs transfected with miR-93-5p inhibitor. In addition, both an miR-93-5p mimic and negative control were transfected into BMSCs. Expression of miR-93-5p was significantly increased in the model group compared with control samples. An miR-93-5p inhibitor induced the expression of BMP-2 and ALP. Furthermore, expression of osteogenesis-related markers (BMP-2, OPN, RUNX-2, and Osterix) was higher in the miR-93-5p inhibitor group, as revealed by qPCR and western blotting. Additionally, in vitro experimentation revealed that an miR-93-5p mimic decreased BMP-2 and OPG expression, but increased RANKL expression. In summary, the miR-93-5p inhibitor could promote osteogenic differentiation by increasing BMP-2 expression during the development of TIONFH. Thus, miR-93-5p may have potential as a therapeutic target for TIONF treatment.

Keywords: TIONFH, miR-93-5p, bone marrow stromal cells, osteogenesis
Introduction

Osteonecrosis of the femoral head (ONFH) is a frequently occurring disease, characterized by femoral head collapse accompanied by degenerative changes of the hip [1]. Trauma-induced ONFH (TIONFH) is a comment type of ONFH, which is preceded by traumatic hip dislocation, femoral neck fracture, or slipped capital femoral epiphysis [2]. Without timely and effective treatment, TIONFH patients may be left with permanent disability. Reportedly, TIONFH patients can be treated with core decompression of the hip and total replacement of the hip [3], however, the long-term prognosis is poor [4]. Therefore, there is urgent need to find biological approaches to treat TIONFH.

Growing evidences have revealed that the ability of bone marrow mesenchymal stem cells (BMSCs) to differentiate plays a crucial role in the treatment of patients with ONFH [5-7]. Indeed, BMSCs have shown significant osteogenic potential in various animal models of bone repair [8, 9], and stem cell therapies have been applied to clinical treatment of ONFH [10]. A recent meta-analysis has reported that BMSC implantation has a positive therapeutic effect on patients with ONFH [11]. In the past few years, microRNAs (miRNAs), a type of small noncoding RNAs with the ability to repress gene expression, are increasingly recognized as playing a functional role in the pathogenesis and treatment of ONFH. Dai et al. indicated that miR-217 promoted osteogenic differentiation via inhibition of the Dickkopf WNT signaling pathway inhibitor 1 during the development of steroid-induced ONFH [12]. Moreover, a study reported by Liao et al. observed that overexpression of miR-122-5p might downregulate sprouty RTK signaling antagonist 2, leading to alleviate the development of ONFH [13]. However, the role of miRNA in the pathogenesis of TIONFH remains poorly understood.

In our former study, we examined abnormal miRNAs in patients with TIONFH and identified a total of 35 up-regulated miRNAs (including miR-93-5p) [14]. Subsequently, cell culture experiments were conducted and confirmed that upregulation of miR-93-5p inhibited osteogenic differentiation by reducing the expression level of bone morphogenetic protein 2 (BMP-2) during the development of TIONFH. In previous studies, miR-93-5p has been reported in various types of cancers, including gastric cancer [15], breast cancer [16], and esophageal cancer [17]. Among
these studies, we observe that miR-93-5p mainly functions in cell migration and invasion. Thus, we hypothesize that inhibiting miR-93-5p may promote osteogenic differentiation, but the exact mechanism remains unclear.

In the present study, we used a rabbit model in vivo and BMSCs in vitro to research the role of miR-93-5p in the pathogenesis of TIONFH, providing potential therapeutic targets for TIONFH.

**Methods**

**Animals model establishment and treatment groups**

The experimental protocols were approved by the Animal Ethics Committee at Guangzhou University of Chinese Medicine, and all processes were performed in accordance with the institutional guidelines for animal care. Thirty-two healthy New Zealand white rabbits (16 weeks, males and females, 2.8-3.3 kg) were used for experiments after a seven-day adaptation period under the standard laboratory conditions. Among these, 6 rabbits were set as controls and 24 rabbits underwent traumatic surgery. Rabbits were anesthetized with 3% pentobarbital sodium (1 mL/kg, Sinopharm Chemical Reagent Co., Ltd, China). A posterolateral incision was made in the right hip under aseptic conditions, the joint capsule was cut, and then the femoral head was exposed. Next, a stainless-steel bone-groove knife was used to form an external force fracture in the femoral neck and dislocate the femoral head. Meanwhile, the fracture remained separated for 2 to 3 min. Subsequently, the femoral head was repositioned and secured with sutures and no external fixation. Finally, the wound was injected with antibiotics before being closed in layers.

During the postoperative period, all animals were free to move and no postoperative infection was observed. The left femoral head was used as control (Figure 1). The 24 postoperative animals were randomly divided into three equal-sized groups: the model group (rabbits with TIONFH), the model + BMSCs group (TIONFH rabbits injected with BMSCs), and the model + BMSCs/miR-93-5p inhibitor group (TIONFH rabbits injected with miR-93-5p inhibitor-transfected BMSCs).

**Magnetic resonance imaging (MRI) examinations**

To identify whether the model was successful, an MRI examination was performed after two
weeks treatment. MRI was conducted by a GE signa EXICITE HD 1.5T superconducting MR machine (GE Medical System, Milwaukee, USA). An axial scan was performed by SE/T₁WI, FSE/T₂, and an FSE/T₂ fat suppression sequence using 8-channel receiver head coils. T₁W axial fast multiplanar spoiled gradient-echo images from the hip joint were obtained with the following parameters: slice thickness/spacing, 4/0 mm; acquisition matrix, 256×192; TE/TR, 9/4 ms; TI, 200 ms; flip angle 8°; and field of view, 14×14 cm².

**Isolation and cultivation of BMSCs**

Primary BMSCs were isolated as described previously [18]. In brief, two New Zealand rabbits were anesthetized by injection with 3% pentobarbital sodium (1 mL/kg), and 10 mL of bone marrow was extracted from the femur using a heparinized syringe. The bone marrow was diluted with DMEM high glucose medium (containing 10 % fetal bovine serum) and then centrifuged at 1500 rpm for 5 min. After removing fat, the cells were re-suspended. Next, the cell suspension was centrifuged with 1.073 g/mL Percoll lymphocyte separation medium, and the mononuclear cells located at the junction of the liquid level were collected. After washing twice with the sterile phosphate-buffered saline (PBS), the cells were cultured in DMEM. The cells were seeded in a 100 mm culture dish and cultured at 37 °C in a cell incubator with 5% CO₂. Half of the culture medium was exchanged after 36 h incubation. Cells at 80% confluency were digested with 0.25% trypsin and then centrifuged and passaged at a 1:1 ratio. The 2nd generation cells were given an extended cultivation at 1:3 ratio. Finally, the 3rd generation cells were harvested for following experiments, and then stem cells were identified by flow cytometry.

**Identification of the BMSCs**

To authenticate the phenotypic character, the cell identification kit (Cyagen Biosciences Inc., Guangzhou, China) was used to collect the 3rd generation BMSCs. Afterward, the expression of surface markers (CD34, CD105, CD90, CD73, and CD45) were detected by flow cytometry. Briefly, cells were incubated with FITC-tag for 10 minutes, and then washed twice with PBST. IgG1 was used as control. The expression of cell antibodies was detected by BD Accuri C6 flow cytometry within 6 hours. The experiment was repeated three times.

**Transfection of miR-93-5p inhibitor into rabbit BMSCs**

FEBS Open Bio (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
The miR-93-5p inhibitor (sequence: 5’-CTACCTGCACGAACAGCACTTTC-3’) was compounded by RiboBio Co. Ltd (Guangzhou, China), and then transfected into BMSCs using lipofectamine 2000 according to the manufacturer’s instructions.

**Local injection of BMSCs**

Two weeks after surgery, the femoral head was re-exposed to inject BMSCs. For the model + BMSCs group, 5×10⁶ BMSCs were injected into model animals. In addition, for the model + BMSCs/miR-93-5p inhibitor group, 5×10⁶ miR-93-5p inhibitor- transfected with BMSCs were injected into TIONFH animals through the femoral marrow.

**Quantitative polymerase chain reaction (qPCR) analysis of miR-93-5p**

Peripheral blood of animals in each group was collected for miR-93-5p detection at 2 weeks and 4 weeks after treatment. Total RNA samples were extracted using the TRIzol method. A looped antisense primer (CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCTACCTGC) was used for reverse transcription. QPCR was carried out according to manufacturer instruction using the mirVana™ qRT-PCR miRNA Detection Kit (RiboBio Biotechnology, Guangzhou), and U6 was selected as an internal control.

**Histological examinations and immunohistochemical (IHC) detection**

After 8 weeks, the animals were sacrificed. The femoral head was sampled and fixed in 4% formaldehyde solution for 48 hours. Subsequently, the specimens were decalcified by 10% ethylene diamine tetraacetic acid for 10 to 15 days. Buffer was changed every 3 days. Then, samples were embedded in paraffin and cut into 5-μm-thick sections in the coronal plane. Some sections were analyzed for morphology using histology. The specimens were deparaffinized by xylol, and then re-hydrated in successively decreasing grades of ethanol. Subsequently, the sections were stained with hematoxylin (5-20 min) and eosin (30 s) at room temperature. Histological changes were observed under a Leica stereomicroscope (MZ 6) at 100× magnification.

On the remaining sections, IHC was performed to detect BMP-2 and alkaline phosphatase (ALP) protein expression. In detail, the sections were dewaxed in xylene and rehydrated in ethanol, and washed in Tris-buffered saline (TBS) twice for three minutes. Afterward, sections were incubated
with 3% hydrogen peroxide for 10-15 minutes, and washed with TBS twice for 5 min. Then sections were incubated with sealing solution at 25 °C for 5 min, and washed in TBS. The sections of samples were incubated at 37 °C for 2 h with the following primary antibodies: BMP-2 (dilution 1:300, sc-137087, Santa Cruz Biotechnology) and ALP (dilution 1:200, sc-365765, Santa Cruz Biotechnology). After that, sections were washed with TBS twice for 5 min, incubated with Enhancer reagent at room temperature for 20 min, and rinsed again with TBS. Finally, the sections were treated with HRP Polymer for 30 min at room temperature and stained with Diaminobenzadine. The sections were observed under a Leica stereomicroscope at 100× magnification.

**QPCR assay of osteogenic related genes**

The expression level of osteogenic related genes, including BMP-2, secreted phosphoprotein 1 (OPN), RUNX family transcription factor 2 (RUNX-2), and Osterix, was detected by qPCR. RNA was extracted from the rabbit’s femoral head using Trizol reagent (Invitrogen). The synthesis of first-strand cDNA was performed by PrimeScript™ RT reagent Kit (RR037A, TaKaRa). The SYBR Premix Ex Taq kit (RR420A, TaKaRa) was used to performe qPCR, according to the manufacturer's protocol, on the ABI7500 FAST real-time PCR system under the program: 95 °C for 30 s; 40 cycles of 95 °C for 3 s and 60 °C for 30 s. The relative expression of genes was calculated with the \(2^{-\Delta\Delta Ct}\) method, and \(\beta\)-actin was employed for internal control. The primer sequences are listed in Table 1.

**Western blotting assay**

The protein abundance of osteogenic related markers was also tested by western blotting. The femoral head was crushed in liquid nitrogen using a mortar, dissolved in immunoprecipitation assay buffer, and protein was extracted. The protein concentration was measured using the BCA quantitative assay. Protein samples (20 μg) were separated using 12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. Blocking was performed using 5% skim milk powder for 1 h at room temperature. The membrane was incubated with primary antibodies against GAPDH (dilution 1:1400, KM9002, Tianjin Sungene Biotech Co., Ltd.), BMP-2 (dilution 1:1000, sc-137087, Santa Cruz Biotechnology), RUNX-2 (dilution 1:1000, sc-101145, Santa Cruz Biotechnology).
Biotechnology), OPN (dilution 1:1000, sc-21742, Santa Cruz Biotechnology), and Osterix (dilution 1:1000, sc-22538, Santa Cruz Biotechnology) overnight at 4 °C, and then incubated with horseradish peroxidase-labeled secondary antibodies (dilution 1:5000) for 50 min at room temperature. After washing with 0.05% TBST, the protein accumulation was detected by the Millipore ECL Western Blotting Detection System (EMD Millipore).

**Immunofluorescence detection in vitro**

MiR-93-5p mimics were transfected into BMSCs, and nonspecific microRNA was used as negative control (NC). After 48 h infection, osteogenic inducer (containing 50 mg/L ascorbic acid, 0.1 μmol/L dexamethasone, and 10 mmol/L β-glycerophosphate) was supplemented, and then cells were cultured for 7 days. Next, after removing the culture solution, cells were fixed with 4% paraformaldehyde, and permeabilized with 1% Triton X-100 for 10 min. Transfected cells were washed with PBS and blocked with 3% BSA for 30 min. Subsequently, cells were incubated overnight with BMP-2 primary antibody (dilution 1:1000, ab6285, Abcam, Cambridge, UK) at 4 °C, and then incubated with secondary antibody (dilution 1:2000, ab150115, Abcam, Cambridge, UK) at room temperature for 30 min. Finally, cells were incubated for 10 min with 4, 6-diamidino-2-phenylindole (10 μg/mL) for nuclear staining at room temperature. Immunofluorescence was examined using a ZEISS LSM 800 at 200× magnification. Furthermore, total protein of these cells was isolated using RIPA buffer, and the protein expression level of TNF receptor superfamily member 11b (OPG) and receptor activator of nuclear factor-kappaB Ligand (RANKL) was determined by using Western blotting. The primary antibodies included anti-OPG rabbit polyclonal antibody (dilution 1:300, Abcam, Cambridge, UK), anti-RANKL (dilution 1:1000, sc-377079, Santa Cruz Biotechnology), and GAPDH (dilution 1:1400, KM9002, Tianjin Sungene Biotech Co., Ltd.).

**Statistical analysis**

All experiments were repeated three times. Data was presented as means ± standard deviation (SD). The GraphPad Prism 8.0 software was used to analyze results. One-way analysis of variance (ANOVA) followed by a Dunnett’s multiple comparison test was selected to calculate statistical differences. \( P < 0.05 \) was considered significant.
Results

The appearance of the femoral head

After modeling, we observed the appearance and cross-section of the femur. Figure 1A showed the exposed femoral head, and the diameter of the femoral head was larger in the control group than in the model group (Figure 1B). In addition, the cross-sectional view showed that the model side femur was white, presenting ischemic necrosis (Figure 1C), while the bone marrow of the normal femur was bright (Figure 1D).

MRI examination of femoral head

The image of the right hip showed a double-line sign accompanied by collapse of the femoral head (Figure 2A). Additionally, a crescent sign was also observed. These characteristics indicated that the TIONFH model was obtained. Figure 2B displays the MRI examination of normal femoral head.

Identification of BMSCs

The results demonstrated that the isolated cell expression was positive for mesenchymal stem cells markers, including CD73, CD90, and CD105 (Figure 3A-3C); and was negative for the hematopoietic marker CD34 (Figure 3D) and leukocyte marker CD45 (Figure 3E). The results were in line with BMSCs phenotypic characteristics.

The expression level of miR-93-5p

The mRNA expression level of miR-93-5p in the model group was markedly higher than that in the control group (\(P < 0.01\)), and it was gradually increased in the model group during the treatment process. Ranging from 2 to 4 weeks, a significant decrease of miR-93-5p was observed in the model + BMSCs group, and a similar trend was found in the model + BMSCs/miR-93 5p inhibitor group (all \(P < 0.01\)). Furthermore, the expression level of miR-93-5p was observably lower in the inhibitor group than in the remaining three groups (Figure 4).

Histological observations and IHC analysis

As shown in Figure 5, the sections stained with hematoxylin-eosin showed the femur was intact without osteoclasts in the normal group, suggesting that the samples were healthy without
inflammation. However, obvious osteonecrosis with more empty lacunae was observed in the model group. Compared with the model group, fewer empty lacunae and more osteoblasts were observed in the model + BMSCs group and model + BMSCs/miR-93-5p inhibitor group. Additionally, we found the number of empty lacunae in the model + BMSCs/miR-93-5p inhibitor group was less than in the model + BMSCs groups.

BMP-2 and ALP protein levels were detected by IHC analysis. The representative image is shown in Figure 6A. The level of BMP-2 (Figure 6B) and ALP (Figure 6C) was significantly lower in the model group than the control group (all $P < 0.01$). The model + BMSCs/miR-93-5p inhibitor group exhibited higher levels of BMP-2 and ALP protein than the model group ($P < 0.01$), suggesting the inhibitor group had higher osteoblast differentiation ability.

**Osteogenic related markers detected by qPCR and western blotting assay**

The mRNA expression level of osteogenic related genes was detected by qPCR. The expression of BMP-2, which was considered an important factor in stimulating bone formation, was remarkably decreased in the model group compared with the control group ($P < 0.01$). Additionally, BMP-2 was significantly increased in the model + BMSCs/miRNA-93-5p inhibitor group than the model group ($P < 0.01$). Compared to the model + BMSCs group, BMP-2 expression level in the model + BMSCs/miR-93-5p was significantly increased ($P < 0.05$). Notably, OPN, RUNX-2, and Osterix showed similar tendencies as BMP-2 (Figure 7A). Furthermore, the expression of osteogenesis proteins was detected by western blotting, and the protein abundance had consistent trend with the qPCR data. In brief, the expression of BMP-2, OPN, RUNX-2, and Osterix in the model group was significantly lower than the control group, which was drastically higher in the model + BMSCs group than in the model group ($P < 0.01$). In addition, we observed OPN, RUNX-2, and Osterix were significantly higher in the model + BMSCs group than in the model group ($P < 0.01$), and the level of these proteins was observably increased in the model + BMSCs/miR-93-5p inhibitor group than in the model + BMSCs group ($P < 0.05$, Figure 7B and 7C).

**Immunofluorescence detection in vitro**

To determine whether miR-93-5p could repress BMP-2 expression in BMSCs, we transfected the
miR-93-5p mimic or NC into BMSCs. Immunofluorescence revealed that BMP-2 expression was induced during osteogenic differentiation of BMSCs (Figure 8A). Additionally, we observed that the BMP-2 expression was weak in the normal BMSCs group. Compared with the BMSCs group, the protein expression of BMP-2 was significantly higher in other groups. In addition, the level of BMP-2 in the inducer + BMSCs/miR-93-5p mimic group was significantly lower than the inducer + BMSCs and inducer + BMSCs/miR-93-5p NC groups ($P < 0.01$). These findings showed that BMP-2 was suppressed by miR-93-5p mimic transfection, suggesting that impaired differentiation of BMSCs was caused by miR-93-5p overexpression (Figure 8B).

Moreover, we detected the protein expression of OPG and RANKL. Compared with the BMSCs group, the expression of OPG in the inducer + BMSCs and the inducer + BMSCs/miR-93-5p NC was significantly increased ($P < 0.01$). However, a decreased OPG was observed in the inducer + BMSCs/miR-93-5p mimic group ($P < 0.01$), which almost recovered to normal level. RANKL expression were significantly declined in inducer + BMSCs as well as the inducer + BMSCs/miR-93-5p NC groups ($P < 0.01$), which was increased by treatment with miR-93-5p mimic (Figure 9).

Discussion

TIONFH is mainly caused by decreased blood flow to the femoral head and lesion of bone trabecula, resulting in articular cartilage collapse and hip joint dysfunction [19]. Convincing evidence indicates that BMSCs may be critically involved in bone differentiation and tissue regeneration [20, 21], hence, understanding the osteogenic differentiation mechanism of BMSCs is important to provide new insight for increasing treatment options. Additionally, additional studies have suggested that osteogenic differentiation and bone remodeling processes are regulated by miRNAs [22-24].

We previously confirmed that miRNA-93-5p suppressed osteogenic differentiation of hBMSCs by targeting BMP-2 [14], but the specific function of miR-93-5p in osteogenic differentiation remained unclear. In the current study, the effect of miR-93-5p on osteonecrosis was investigated in a rabbit model. We observed that injection of the miR-93-5p inhibitor could promote osteogenic differentiation, and the effect of the inhibitor was better than that of the BMSCs group.
Additionally, with a series of in vivo assays, we observed that expression of osteogenic related proteins (BMP-2, OPN, RUNX-2, and Osterix) was increased, whereas miR-93-5p expression was reduced during the osteogenic differentiation of BMSCs. Furthermore, during in vitro experiments, addition of miR-93-5p mimic in osteoblast induced BMSCs, resulted in an overexpression of RANKL and low expression of BMP-2 as well as OPG. All the above evidences further supported that BMP-2 was regulated by miR-93-5p during osteogenic differentiation. Moreover, histology and immunohistochemistry indicated that the effect of bone differentiation in the inhibitor group was better than that in the model and BMSCs groups.

MiRNA-93-5p, as a member of miR106b-25 family, is located on chromosome 11q22.1 [25]. Recently, miRNA-93-5p has been widely investigated and reported that play a role in various types of cancer [26, 27] and cell differentiation [28]. Furthermore, emerging findings have demonstrated that the bone remodeling processes and osteogenic differentiation are regulated by miRNA-93-5p. Quan et al. found that miR-93-5p served a crucial role in osteoclastogenesis and vasculogenesis [29]. Meanwhile, Xu et al. observed that miR-93-5p suppressed osteogenic differentiation of mouse BMSCs by targeting Smad5 [30]. In our previous study, an increased miR-93-5p was observed in TIONFH patients, which could inhibit osteogenic differentiation and was associated with BMP-2 reduction [14]. However, the specific mechanism of miR-93-5p affects BMP-2 expression is still unclear. In this study, we further confirmed the effect of miR-93-5p on osteogenic differentiation using a rabbit TIONFH model. Inhibition of miR-93-5p could promote BMSCs osteogenic differentiation and increased the expression of osteogenesis-related proteins, which was consistent with the previous results.

The key findings of this study demonstrated that osteogenesis-related proteins, including BMP2, OPN, RUNX-2, and Osterix, were regulated by miR-93-5p. BMP-2 is an effective osteoinductive protein that can facilitate osteoblast differentiation and accomplish bone repair [31, 32]. Several studies have reported that BMP-2 could serve as adjuvant therapy in ONFH surgical treatment [33, 34]. Another factor, OPN is a key component in osteoclast attachment to bone during resorption. A recent study reported by Luukkonen observed that OPN was detected in areas of increased bone metabolism [35]. We found the expression level of BMP-2 and OPN in the model +
BMSCs/miR-93-5p inhibitor group was markedly higher than the model group, revealing miR-93-5p inhibition could enhance the ability of bone metabolism. Moreover, RUNX-2 can regulate the formation and differentiation of BMSCs into osteoblasts [36]. In this study, inhibiting miR-93-5p could increase the expression of Runx-2, suggesting that miR-93-5p might suppress the osteogenic differentiation of BMSCs. Osterix encodes a member of the Sp subfamily of Sp/XKLF transcription factors. It is considered as a bone specific transcription factor, which is essential for osteoblast differentiation and bone formation [37]. Similarly, the overexpression of Osterix was observed in the miR-93-5p inhibitor group. Furthermore, a previous study have revealed that addition of exogenous BMP-2 to osteogenic precursor cells (MC3T3-E1) can promote the Runx-2, OPN, and osterix protein expression as well as osteogenic formation, indicating that these genes jointly promote the differentiation of osteogenic [38]. The combined results indicated that miR-93-5p regulated osteogenic differentiation by affecting the expression of BMP-2, OPN, RUNX-2, and Osterix.

To comprehensively explore the mechanism of miR-93-5p in BMSCs osteogenic differentiation, we investigated the association between BMP-2/OPG/RANKL and miR-93-5p using in vitro experiments. We observed that BMP-2 expression was significantly increased in the inducer + NC group, and was dramatically suppressed in the inducer + miR-93-5p mimic group, which were consistent with the prior study [14]. The expression of OPG was significantly increased in the inducer + miR-93-5p NC, and markedly decreased in the inducer + miR-93-5p mimic group. RANKL expression were significantly declined in the inducer + miR-93-5p NC groups, while was increased by treatment with miR-93-5p mimic. Previous study has reported a closely association between the OPG as well as RANKL and the development of ONFH [39]. Song et al. found that proper mechanical stress could promote osteonecrosis recovery via the OPG/RANK/RANKL system [40]. These studies emphasized that OPG and RANKL might be potential therapeutic targets for ONFH. Taken together, we further revealed that miR-93-5p might regulate osteogenic differentiation via affecting the expression of BMP-2, OPG, and RANKL.

The concentrated implantation of BMSCs could relieve hip pain, and prevent the progression of osteonecrosis [41]. Therefore, BMSCs are frequently used for treatment of ONFH, and the clinical
effects have been recognized. In the present study, the results indicated that compared with the BMSCs group, the miR-95-5p inhibitor group demonstrated a stronger effect on regulating osteogenic differentiation. We suggest miR-93-5p as a probable key regulator of osteogenic differentiation, and as a potential therapeutic target for TIONF treatment.

Conclusions
Overall, the results suggested that miR-93-5p had a significant biological effect on the osteogenic differentiation of BMSCs both *in vivo* and *in vitro*. Inhibition of miR-93-5p increased the expression of BMP-2 mRNA and protein, indicating that miR-93-5p could function as osteogenic differentiation suppressors by reducing BMP-2 expression in TIONFH patients. Additionally, we observed that miR-93-5p affected the OPN, RUNX-2, Osterix, OPG, and RANKL expression in the process of osteogenic differentiation. Our results provided evidence that miR-93-5p could be considered as a new therapeutic target for TIONFH. However, further studies on feasibility are still needed to be conducted before miR-93-5p can be targeted for clinical therapy.
Authors' contributions
Conception and design of the research: YZ, WL, QW; acquisition of data: LZ, ZH, HW; analysis and interpretation of data: YZ, YL; statistical analysis: ZZ, PL; obtaining funding: YZ, WL; drafting the manuscript: PL, YF; revision of manuscript for important intellectual content: YF, ZZ, QW. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by National Science Foundation of China (grant number 81774348 and 81874477).

Data availability statement
Research data are not shared.

Conflicts of interest
The authors declare that they have no conflicts of interest.
References

1. Moya-Angeler, J, Gianakos, AL, Villa, JC, Ni, A & Lane, JM (2015) Current concepts on osteonecrosis of the femoral head. *World journal of orthopedics* 6: 590-601.

2. Xu, H, Liao, W, Liu, X, Hu, J, Zou, W, Ning, Y, Yang, Y & Li, Z (2019) Down-regulation of exosomal microRNA-224-3p derived from bone marrow–derived mesenchymal stem cells potentiates angiogenesis in traumatic osteonecrosis of the femoral head. *The FASEB Journal* 33: 8588-8068.

3. Hang, D, Wang, Q, Guo, C, Chen, Z & Yan, Z (2012) Treatment of osteonecrosis of the femoral head with VEGF165 transgenic bone marrow mesenchymal stem cells in mongrel dogs. *Cells Tissues Organs* 195: 495-506.

4. Ramachandran, M, Ward, K, Brown, RR, Munns, CF, Cowell, CT & Little, DG (2007) Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. *The Journal of Bone & Joint Surgery* 89: 1727-1734.

5. Zhun, W, Donghai, L, Zhouyuan, Y, Haiyan, Z & Pengde, K (2018) Efficiency of Cell Therapy to GC-Induced ONFH: BMSCs with Dkk-1 Interference Is Not Superior to Unmodified BMSCs. *Stem cells international* 2018.

6. Wang, Q, Yang, Q, Chen, G, Du, Z, Ren, M, Wang, A, Zhao, H, Li, Z, Zhang, G & Song, Y (2018) LncRNA expression profiling of BMSCs in osteonecrosis of the femoral head associated with increased adipogenic and decreased osteogenic differentiation. *Scientific reports* 8: 9127.

7. Song, H, Tao, L, Wang, F, Wang, W, Wei, Y, Shen, W & Zhou, F (2015) Effect of bone mesenchymal stem cells transplantation on the micro-environment of early osteonecrosis of the femoral head. *International journal of clinical and experimental pathology* 8: 14528.

8. Gu, C, Xu, Y, Zhang, S, Guan, H, Song, S, Wang, X, Wang, Y, Li, Y & Zhao, G (2016) miR-27a attenuates adipogenesis and promotes osteogenesis in steroid-induced rat BMSCs by targeting PPARγ and GREM1. *Scientific reports* 6: 38491.

9. Zhao, X, Wei, Z, Li, D, Yang, Z, Tian, M & Kang, P (2019) Glucocorticoid Enhanced the Expression of Ski in Osteonecrosis of Femoral Head: The Effect on Adipogenesis of Rabbit BMSCs. *Calcified tissue international* 105: 506-517.
10. Im, G (2017) Clinical use of stem cells in orthopaedics. *European Cells and Materials* **33**:183-196.
11. Yuan, H, Zhang, J, Guo, C & Yan, Z (2016) Clinical outcomes of osteonecrosis of the femoral head after autologous bone marrow stem cell implantation: a meta-analysis of seven case-control studies. *Clinics* **71**: 110-113.
12. Dai, Z, Jin, Y, Zheng, J, Liu, K, Zhao, J, Zhang, S, Wu, F & Sun, Z (2019) MiR-217 promotes cell proliferation and osteogenic differentiation of BMSCs by targeting DKK1 in steroid-associated osteonecrosis. *Biomedicine & Pharmacotherapy* **109**: 1112-1119.
13. Liao, W, Ning, Y, Xu, H, Zou, W, Hu, J, Liu, X, Yang, Y & Li, Z (2019) BMSC-derived exosomes carrying microRNA-122-5p promote proliferation of osteoblasts in osteonecrosis of the femoral head. *Clinical Science* **133**: 1955-1975.
14. Zhang, Y, Wei, Q, Ding, W, Zhang, L, Wang, H, Zhu, Y, He, W & Chai, Y (2017) Increased microRNA-93-5p inhibits osteogenic differentiation by targeting bone morphogenetic protein-2. *PloS One* **12**: e0182678.
15. Ma, D, Li, B, Liu, J, Xiao, Y, Yong, X, Wang, S, Wu, Y, Zhu, H, Wang, D & Yang, S (2017) miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway. *Cancer Letters* **408**: 23-32.
16. Xiang, Y, Liao, X, Yu, C, Yao, A, Qin, H, Li, J, Hu, P, Li, H, Guo, W, Gu, C & Zhang, T (2017) MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. *Experimental Cell Research* **357**: 135-144.
17. Liu, MX, Liao, J, Xie, M, Gao, ZK, Wang, XH, Zhang, Y, Shang, MH, Yin, LH, Pu, YP & Liu, R (2018) miR-93-5p Transferred by Exosomes Promotes the Proliferation of Esophageal Cancer Cells via Intercellular Communication by Targeting PTEN. *Biomedical and Environmental Sciences* **31**: 171-185.
18. Soleimani, M & Nadri, S (2009) A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. *Nature protocols* **4**: 102-106.
19. Bachiller, FG-C, Caballer, AP & Portal, LF (2002) Avascular Necrosis of the Femoral Head After Femoral Neck Fracture. *Clinical Orthopaedics and Related Research®* **399**: 87-109.
20. Qin, Y, Wang, L, Gao, Z, Chen, G & Zhang, C (2016) Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. *Scientific reports* 6: 21961.

21. Abdallah, BM, Al-Shammary, A, Khattab, HM, AlDahmash, A & Kassem, M (2016) Bone Marrow Stromal Stem Cells for Bone Repair: Basic and Translational Aspects in *Recent Advances in Stem Cells: From Basic Research to Clinical Applications* (Abdelalim, E. M., ed) pp. 213-232, Springer International Publishing, Cham.

22. Zhang, J, Fu, W, He, M, Xie, W, Lv, Q, Wan, G, Li, G, Wang, H, Lu, G, Hu, X, Jiang, S, Li, J, Lin, MCM, Zhang, Y & Kung, H (2011) MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. *RNA Biology* 8: 829-838.

23. Dong, S, Yang, B, Guo, H & Kang, F (2012) MicroRNAs regulate osteogenesis and chondrogenesis. *Biochemical and Biophysical Research Communications* 418: 587-591.

24. Weilner, S, Skalicky, S, Salzer, B, Keider, V, Wagner, M, Hildner, F, Gabriel, C, Dovjak, P, Pietschmann, P, Grillari-Voglauer, R, Grillari, J & Hackl, M (2015) Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. *Bone* 79: 43-51.

25. Meng, H, Li, YY, Han, D & Zhang, CY (2019) MiRNA-93-5p promotes the biological progression of gastric cancer cells via Hippo signaling pathway. *European review for medical and pharmacological sciences* 23: 4763-4769.

26. Wang, L, Liu, S, Mao, Y, Xu, J, Yang, S, Shen, H, Xu, W, Fan, W & Wang, J (2018) CircRNF13 regulates the invasion and metastasis in lung adenocarcinoma by targeting miR-93-5p. *Gene* 671: 170-177.

27. Meng, X, Joosse, SA, Müller, V, Trillsch, F, Milde-Langosch, K, Mahner, S, Geffken, M, Pantel, K & Schwarzenbach, H (2015) Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. *British Journal of Cancer* 113: 1358-1366.

28. Wu, Y, Zuo, J, Zhang, Y, Xie, Y, Hu, F, Chen, L, Liu, B & Liu, F (2013) Identification of miR-106b-93 as a negative regulator of brown adipocyte differentiation. *Biochem Biophys Res
29. Quan, H, Liang, M, Li, N, Dou, C, Liu, C, Bai, Y, Luo, W, Li, J, Kang, F, Cao, Z, Yang, X, Jiang, H & Dong, S (2018) LncRNA-AK131850 Sponges MiR-93-5p in Newborn and Mature Osteoclasts to Enhance the Secretion of Vascular Endothelial Growth Factor a Promoting Vasculogenesis of Endothelial Progenitor Cells. *Cellular Physiology and Biochemistry* **46**: 401-417.

30. Xu, L, Li, X, Liu, Y, Kong, Q, Long, D & Li, S (2015) miR-93-5P suppresses osteogenic differentiation of mouse C3H10T1/2 cells by targeting Smad5. *Chinese journal of reparative and reconstructive surgery* **29**: 1288-1294.

31. Minamizato, T, Sakamoto, K, Liu, T, Kokubo, H, Katsube, K-i, Perbal, B, Nakamura, S & Yamaguchi, A (2007) CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. *Biochemical and Biophysical Research Communications* **354**: 567-573.

32. Mbalaviele, G, Sheikh, S, Stains, JP, Salazar, VS, Cheng, SL, Chen, D & Civitelli, R (2005) Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. *Journal of cellular biochemistry* **94**: 403-418.

33. Sun, W, Li, Z, Gao, F, Shi, Z, Zhang, Q & Guo, W (2014) Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. *PLoS One* **9**: e100424.

34. Peng, W & Wang, L (2017) Adenovirus-Mediated Expression of BMP-2 and BFGF in Bone Marrow Mesenchymal Stem Cells Combined with Demineralized Bone Matrix For Repair of Femoral Head Osteonecrosis in Beagle Dogs. *Cellular Physiology and Biochemistry* **43**: 1648-1662.

35. Luukkonen, J, Hilli, M, Nakamura, M, Ritamo, I, Valmu, L, Kauppinen, K, Tuukkanen, J & Lehenkari, P (2019) Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. *Histochemistry and Cell Biology* **151**: 475-487.

36. Ma, X, Liu, Z, Ma, J, Han, C & Zang, J (2010) Dynamic expression of Runx2, Osterix and AJ18 in the femoral head of steroid-induced osteonecrosis in rats. *Orthopaedic Surgery* **2**: 1648-1662.
278-284.

37. Zhang, C, Li, Y, Cornelia, R, Swisher, S & Kim, H (2012) Regulation of VEGF expression by HIF-1α in the femoral head cartilage following ischemia osteonecrosis. Scientific Reports 2: 650.

38. Yin, N, Zhu, L, Ding, L, Yuan, J, Du, L, Pan, M, Xue, F & Xiao, H (2019) MiR-135-5p promotes osteoblast differentiation by targeting HIF1AN in MC3T3-E1 cells. Cellular & molecular biology letters 24: 51.

39. Chen, B, Du, Z, Dong, X, Li, Z, Wang, Q, Chen, G, Zhang, G & Song, Y (2019) Association of Variant Interactions in RANK, RANKL, OPG, TRAF6, and NFATC1 Genes with the Development of Osteonecrosis of the Femoral Head. DNA and cell biology 38: 734-746.

40. Fu, D, Qin, K, Yang, S, Lu, J, Lian, H & Zhao, D (2020) Proper mechanical stress promotes femoral head recovery from steroid-induced osteonecrosis in rats through the OPG/RANK/RANKL system. BMC musculoskeletal disorders 21: 281.

41. Wang, B, Sun, W, Shi, Z, Zhang, N, Yue, D, Guo, W, Xu, S, Lou, J & Li, Z (2010) Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Archives of Orthopaedic and Trauma Surgery 130: 859-865.
**Figure legends**

**Figure 1.** Surgical procedure of traumatic-induced osteonecrosis of the femoral head. 
(A) Exposed femoral head. (B) Measurement and appearance of the animal femoral head in normal and model groups. (C) Cross-sectional view of the TIONFH. (D) The cross-sectional view of the normal femoral head. The region in white is the necrotic area, while the region showing redness is the normal area. We observe that the model side femur is white, presenting ischemic necrosis, and the bone marrow of the normal femur is bright.

**Figure 2.** MRI examination of femoral head. (A) MRI image of TIONFH. (B) MRI image of normal femoral head. The crescents and collapses are indicated by red arrows.

**Figure 3.** Detection of the surface markers of BMSCs by flow cytometry. (A) CD73, (B) CD90, (C) CD105; (D) CD34; and (E) CD45. Red line represents negative control and blue line represents test sample. Results showed that BMSCs were positive for CD73, CD90, and CD105, while negative for CD45 and CD34.

**Figure 4.** The gene expression of miR-93-5p detected by qPCR. There are eight rabbits used for each group (n = 8) and data were expressed as mean ± SD. Differences between two groups were determined by one-way ANOVA. **P < 0.01 vs. the control group; ## P < 0.01 vs. the model group; & P < 0.05, && P < 0.01 vs. the model + BMSCs group.**

**Figure 5.** HE staining of rabbit femoral heads in different groups (scale bar = 20 µm, n = 8). The model group showed numerous empty lacunae (black arrow) surrounded by necrotic marrow cells. Fewer empty lacunae and more osteoblasts were observed in the model + BMSCs group and model + BMSCs/miR-93-5p inhibitor group. **Figure 6.** Immunohistochemical staining of ALP and BMP-2. 
(A) ALP and BMP-2 expression detected by IHC staining (scale bar = 20 µm). Brown represents positive signals. (B) Quantitative analysis of BMP-2 protein expression level. (C) Quantitative analysis of ALP protein expression level. There were eight animals for each group (n = 8) and data were expressed as mean ± SD. Differences between two groups were determined by one-way ANOVA. **P < 0.01 vs. the control group; ## P < 0.01 vs. model group; & P < 0.05 vs. the model + BMSCs group.**
Figure 7. Inhibition of miR-93-5p promoted osteogenic differentiation in the TIONFH rabbit. (A) The expression levels of osteogenic-related genes (BMP-2, OPN, RUNX-2, and Osterix) measured by qPCR. (B) The protein expression level of BMP-2, OPN, RUNX-2, and Osterix measured by western blotting. (C) Quantified results of BMP-2, OPN, RUNX-2, and Osterix proteins in the different groups. Values are shown as mean ± SD, n = 8 in each group. Differences between two groups were determined by one-way ANOVA. ** P < 0.01 vs. the control group, ## P < 0.01 vs. the model group, & P < 0.05 vs. the model + BMSCs group.

Figure 8. Overexpression of miR-93-5p suppressed the BMP-2 expression level in vitro. (A) Immunofluorescence images showing BMP-2 staining of the cells in the different groups (scale bar = 10 µm). (B) Quantitative analysis of BMP-2 protein expression level in each group. Values are shown as mean ± SD, n = 3 in each group. Differences between two groups were determined by one-way ANOVA. ** P < 0.01 vs. the BMSCs group, ## P < 0.01 vs. the osteogenic inducer + BMSCs group, && P < 0.01 vs. the inducer + BMSCs/miR-93-5p NC group.

Figure 9. Overexpression of miR-93-5p inhibited the OPG expression and increased the RANKL expression. Data are represented as mean ± SD, n = 3 in each group. Differences between two groups were determined by one-way ANOVA. ** P < 0.01 vs. the BMSCs group, ## P < 0.01 vs. the osteogenic inducer + BMSCs group, && P < 0.01 vs. the inducer + BMSCs/miR-93-5p NC group.
Table 1. Primer sequences for quantitative real-time polymerase chain reaction (qPCR)

| Gene   | Forward (5'-3')          | Reverse (5'-3')          |
|--------|--------------------------|--------------------------|
| BMP2   | GGTGGAATGACTGGATTGT      | GAGATAGCAGCTGAGTTCTGT    |
| RUNX2  | CAGCACTCCATATCTCTACTAT   | CTTCCATCAGCGTCAACA       |
| Osterix| CAGGCTATGCTAATGATTACC    | GCCAGACAGTCAGAAGAG       |
| OPN    | ATGGCTTTTCATTGGAGTTGCTTG | TGGTTTGCCTTTCGCTGTTCG    |
| β-actin| ATGCTGCTTACATGTCTCGAT    | AGCAGAGATGGAAAGTCAAA     |
